Content
Yahoo Finance Community
09/18
Comment
Updated data on the drug should be released by Candel soon.Investors are awaiting the results of the trial against glioblastoma cancer in patients who were given up to 6 doses of the drug.The results published in the most prestigious health journal "Nature" showed that with the administration of a single dose, patients lived more than twice as long as with the traditional drug/treatment.I would not be surprised if Candel published updated results again a year later in the same journal.If the results are good, Candel should have a market value of between 3-4B.There is currently no drug in development that achieves these survival rates in brain cancer, Candel could ask the FDA for authorization for this drug to be supplied for compassionate use or for emergency reasons....
Votes:
1
0
Yahoo Finance Community
09/18
Comment
Very interesting. Remember. The CEO has said repeatedly that Candel has been talking/negotiating/looking for a partnership or collaboration with a big pharmaceutical company since the beginning of the year. IMO.Candel has two options: sign an agreement before the data on glioblastoma cancer is read out or wait if the results of the cancer trial are positive and hold off on negotiating a partnership/collaboration agreement until these data are announced. We all know that if the data are good Candel will wait and sell the bear skin at a higher price. We will soon find out because the results of this trial are very close to being announced to the market....
Votes:
1
0
Yahoo Finance Community
09/20
Comment
Very interesting to remember the most important dates in relation to the trial reading that are very close to being announced..The first reading that the market/investors are waiting for is close to being announced in the next few weeks in relation to glioblastoma cancer, waiting for the survival rate of patients who received up to 6 doses of the drug that Candel has developed.The current MC is $250 million... once the brain cancer and 2 prostate cancer results are published before the end of the year, the MC will become $1 billion, which will be a SP of ~$32... this is where they could make an offer. Remember that they have cash until Q1 2025... And in Q1 2025 they will have data on pancreatic cancer and non-small cell lung cancer that will increase the MC to over $2 billion and a SP of over $70... the rest will depend …...
Votes:
1
0
Yahoo Finance Community
09/20
Comment
In the last month, the value of the shares has risen by more than 50%, some big investors are buying and accumulating a large amount of shares without making a fuss.It is becoming increasingly difficult for these investors to buy cheap shares, and the buying and accumulating is driving up the shares without attracting the attention of the market and many investors....
Yahoo Finance Community
09/21
Comment
I think a big announcement is coming.IMO.My theory is that Candel hit the ATM yesterday, "500,000 new shares were transferred to one or more investors yesterday at a price of $7.50-$7.75."Candel should already have the data in their hands from the trial they are conducting in relation to glioblastoma cancer.My guess is that they are very good and that there is no drug in development that shows a higher survival rate in this type of brain cancer.I still maintain that there are large investors who are investing and accumulating a large amount of shares without making any noise....
Quantexa News
09/21
Candel Therapeutics Inc (CADL) Stock Price Reaches $7.54: What Factors Are Influencing This Level?
H.C. Wainwright has recently initiated Candel Therapeutics Inc (CADL) stock to Buy rating, as announced on December 2, 2022, according to Finviz . Earlier, on November 19, 2021, BMO Capital Markets ha...
Yahoo Finance Community
09/21
Comment
Here is where we stand with tax policy:Kamala Harris and Biden together stated last winter that they would liketo tax long-term capital gains as "ordinary income". So, an CADL investorin a 24% tax bracket selling his stock would be taxed $2,400 instead of$1,500 for his $10,000 capital gain.But Harris/Biden also don't like Trump's 2017 tax cuts, so letting themexpire next year would turn a 24% marginal tax bracket into a 28% taxbracket and the stock sale would be taxed $2,800. That would almostDOUBLE it! Mr. Trump likes the LT gain tax right where it is at 15%.Harris/Biden have also stated that the top corporate tax rate (the one thataffects CADL the most) should be increased from 21% currently to 28%, anincrease of 33% on this company that would certainly hurt it's performanceand stock price.Mr. Trump wants to reduce the corporate rate from 21% to 15%. Like the LTgain tax proposals, …...
Votes:
1
0
Yahoo Finance Community
09/23
Comment
I've been saying this for weeks.It's very clear that there is a group of investors who are investing in the company's capital, causing the value of the shares to only rise by 50% in the last month, when in reality, if you look at the data presented by Summit, Candel should be worth several billion at this time."I continue to maintain that there are large investors who are investing and accumulating a large number of shares without making any noise."The fund sentiment score indicates that a lot of money is being accumulated by funds in Candel.This index, which is set from 0 to 100, shows an investment accumulation of funds of 99.19%...
Votes:
2
2
Yahoo Finance Community
09/24
Comment
Candel published the first results of the trial it is carrying out in relation to glioblastoma cancer in October 2023 in the most important journal in the world in the health sector "Nature". IMO. Candel could publish the most updated results a year later in the same journal, we must stay alert. If they are good, Candel could request authorization from the FDA for compassionate use or emergency cases, as it is the most aggressive brain cancer. The current treatment that has not been modified for more than 20 years only grants a survival of 6-9 months. The results to date of the drug that Candel is developing doubled survival in October 2023....
Votes:
5
1
Quantexa News
09/30
Rhumbline Advisers Invests $143,000 in Candel Therapeutics, Inc. (NASDAQ:CADL)
Rhumbline Advisers bought a new position in Candel Therapeutics, Inc. ( NASDAQ:CADL – Free Report ) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commis...
Quantexa News
10/03
Estuardo Aguilar-Cordova Sells 1,800 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of the business’s stock in a transaction on Thursday, October 3rd. The shares wer...
Quantexa News
10/03
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of Candel Therapeutics stock in a transaction on Thursday, October 3rd. The sha...
Quantexa News
10/03
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of Candel Therapeutics stock in a transaction on Thursday, October 3rd. The sha...
Quantexa News
10/03
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of Candel Therapeutics stock in a transaction on Thursday, October 3rd. The share...
Yahoo Finance News
10/04
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Read full article GlobeNewswire Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting Candel Therapeutics Fri, Oct 4, 2024, 9:00...
Quantexa News
10/04
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of Candel Therapeutics stock in a transaction that occurred on Thursday, October...
Quantexa News
10/04
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of the stock in a transaction dated Thursday, October 3rd. The stock was sold a...
Quantexa News
10/06
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells $12,330.00 in Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of the stock in a transaction dated Thursday, October 3rd. The stock was sold at...
Quantexa News
10/06
Estuardo Aguilar-Cordova Sells 1,800 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of the firm's stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an ave...
Quantexa News
10/15
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares
Candel Therapeutics, Inc. ( – ) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average pric...
Quantexa News
10/15
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction that occurred on Monday, October 14th. The stock w...
Quantexa News
10/15
Estuardo Aguilar-Cordova Sells 15,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the business's stock in a transaction on Friday, October 11th. The shares w...
Quantexa News
10/15
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells 15,000 Shares of Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were so...
Quantexa News
10/15
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction that occurred on Monday, October 14th. The stock w...
Quantexa News
10/16
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares of Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction that occurred on Friday, October 1...
Quantexa News
10/16
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares of Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction that occurred on Friday, October...
Quantexa News
10/16
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the business's stock in a transaction on Monday, October 14th. The shares w...
Quantexa News
10/16
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells 15,000 Shares of Stock
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm's stock in a transaction on Monday, October 14th. The shares were so...
Quantexa News
10/16
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) saw a significant decrease in short interest in September. As of September 30th, there was short interest totalling 1,590,000 shares, a decrea...
Quantexa News
10/16
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) saw a significant decrease in short interest in September. As of September 30th, there was short interest totalling 1,590,000 shares, a decr...
Quantexa News
10/17
Estuardo Aguilar-Cordova Sells 15,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction on Friday, October 11th. The sha...
Quantexa News
10/17
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm’s stock in a transaction on Friday, October 11th. The shares were so...
Quantexa News
10/17
Estuardo Aguilar-Cordova Sells 15,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction dated Monday, October 14th. The stock was sold a...
Quantexa News
10/17
Estuardo Aguilar-Cordova Sells 15,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at...
Quantexa News
10/17
Estuardo Aguilar-Cordova Sells 15,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction on Friday, October 11th. The sha...
Quantexa News
10/17
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) was the target of a large drop in short interest in September. As of September 30th, there was short interest totalling 1,590,000 shares, a dr...
Quantexa News
10/18
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells $90,750.00 in Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction dated Friday, October 11th. The st...
Quantexa News
10/18
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells 15,000 Shares of Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the business’s stock in a transaction dated Friday, October 11th. The shares...
Yahoo Finance News
10/28
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) Candel Therapeutics Candel Therapeutics Mon, Oct 28, 2024, 8:00...
Yahoo Finance News
11/05
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
BREAKING Donald Trump wins the 2024 presidential election Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indicatio...
Quantexa News
11/07
Candel Therapeutics (NASDAQ:CADL) Stock Price Up 2.5% – Time to Buy?
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) rose 2.5% on Wednesday . The company traded as high as $5.43 and last traded at $5.33. Approximately 217,298 shares traded hands during tradin...
Quantexa News
11/07
Candel Therapeutics (NASDAQ:CADL) Stock Price Up 2.5% – Time to Buy?
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report )'s share price rose 2.5% during trading on Wednesday . The company traded as high as $5.43 and last traded at $5.33. Approximately 217,298 sh...
Quantexa News
11/07
Candel Therapeutics (NASDAQ:CADL) Stock Price Up 2.5% - Time to Buy?
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) rose 2.5% on Wednesday . The company traded as high as $5.43 and last traded at $5.33. Approximately 217,298 shares traded hands during tradin...
Yahoo Finance News
11/07
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 Candel Therapeutics Candel Therapeutics Thu, Nov 7, 2024, 8:00 AM 4 min read In This Article: CADL -4.50% NEEDHAM, Mass.,...
Yahoo Finance News
11/14
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Candel Therapeutics Thu, Nov 14, 2024, 5:00 AM 10 min read In This Article: CADL +0.23% Candel Therapeu...
Quantexa News
11/14
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024 at 08:00 AM EST NEEDHAM, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical stage biopharmaceutical company focus...
Quantexa News
11/14
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
The Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan to the end of Q1 2025 NEEDHAM, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Candel Th...
Quantexa News
11/17
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,780,000 s...
Quantexa News
11/17
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,780,000...
Quantexa News
11/19
Candel Therapeutics Advances in Cancer Trials Amid Financial Challenges
Candel Therapeutics, Inc. ( (CADL) ) has released its Q3 earnings. Here is a breakdown of the information Candel Therapeutics, Inc. presented to its investors. Don't Miss our Black Friday Offers: D...
Quantexa News
11/19
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 8.5% in October
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,780,000 s...
Quantexa News
11/19
What is HC Wainwright's Estimate for CADL Q4 Earnings?
Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Equities researchers at HC Wainwright issued their Q4 2024 earnings estimates for shares of Candel Therapeutics in a report issued on Monday, No...
Quantexa News
11/22
Research Analysts Issue Forecasts for CADL FY2024 Earnings
Candel Therapeutics, Inc. ( NASDAQ:CADL – Free Report ) – Stock analysts at HC Wainwright decreased their FY2024 EPS estimates for Candel Therapeutics in a research report issued to clients and invest...
Yahoo Finance Community
11/22
Comment
I am a retired Immunologist from NCI. I had done extensive work in tumor Immunology. However my contributions were negligible compared to CADL CEO. I wish to tell you that CADL is developing a very novel idea to treat tumors using lytic adenovirus. I hope they are successful. If they are I tell you that CADL will go to 100 to 400 in no time!!...
Votes:
9
1
Yahoo Finance Community
11/27
Comment
Paul Peter Tak (CADL CEO)has started purchasing additional shares of CADL in accordance with his stated plan to do so.He also congratulated REPL for their breakthrough designation and BLA submission for their viral immunotherapy for melanonoma....
Votes:
1
1
Quantexa News
12/01
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 18.0% in November
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totallin...
Quantexa News
12/03
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 18.0% in November
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalli...
Quantexa News
12/03
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Growth in Short Interest
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 2,100,000 shares, a growth of 18.0...
Quantexa News
12/03
Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 20,392 Shares
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) CTO Seshu Tyagarajan sold 20,392 shares of the firm's stock in a transaction on Friday, November 29th. The shares were sold at an average pr...
Quantexa News
12/03
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Sells 20,392 Shares of Stock
Candel Therapeutics, Inc. ( – ) CTO Seshu Tyagarajan sold 20,392 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $4.56, for a t...
Quantexa News
12/03
Candel Therapeutics, Inc. (NASDAQ:CADL) Insider William Garrett Nichols Sells 13,935 Shares
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) insider William Garrett Nichols sold 13,935 shares of Candel Therapeutics stock in a transaction on Friday, November 29th. The shares were s...
Quantexa News
12/04
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Sells 20,392 Shares of Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) CTO Seshu Tyagarajan sold 20,392 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average...
Quantexa News
12/04
Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 20,392 Shares of Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) CTO Seshu Tyagarajan sold 20,392 shares of the firm's stock in a transaction on Friday, November 29th. The stock was sold at an average pric...
Quantexa News
12/04
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,935 Shares of Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider William Garrett Nichols sold 13,935 shares of Candel Therapeutics stock in a transaction on Friday, November 29th. The shares were sol...
Quantexa News
12/05
Candel Therapeutics, Inc. (NASDAQ:CADL) Insider William Garrett Nichols Sells 13,935 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider William Garrett Nichols sold 13,935 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock...
Yahoo Finance Community
12/05
Comment
@excalibur; How do you see the Option Market providing positive sentiment? Clearly the Out of the Money January $4 Put strikes have the highest open interest providing a whopping 45% premium versus the December $4 Put strikes, with less Open Interest, providing a 25% premium. (Still incredibly high premium percentage with only 15 days until expiration).To me, this indicates that the derivative markets are anticipating the release of the data post Dec. 20th, but are hedging for an earlier release.But more to the point of my question to you..., taking into consideration the 14+% gain today along with the fact the CADL's share price has climb above 5/share, it has not reduced the Premiums mentioned above. Therefore, I would suggest that the Option Market is shows a consistent heightened level of fear going into the data releases.Personally, "selling to Open" a "cash covered Out of the Money $4 strike January …...
Quantexa News
12/06
William Garrett Nichols Sells 13,935 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider William Garrett Nichols sold 13,935 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock...
Quantexa News
12/06
Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $63,543.60 in Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider William Garrett Nichols sold 13,935 shares of Candel Therapeutics stock in a transaction dated Friday, November 29th. The stock was so...
Yahoo Finance Community
12/06
Comment
With in arm distance CADL will report its bombastic results with its clinical trial. It will be a game changer for ever how solid tumors are treated and possible cured. It is a super charged technology and will have very very wide implications. It definitely will give hope and opportunity for patients to smile. I wish great luck to CADL CEO and its employees....
Votes:
6
1
Quantexa News
12/06
Candel Therapeutics Inc (CADL) 20 Days SMA touch 8.82%: Odds are Looking very much in favour
Witnessing the stock's movement on the chart, on Thursday, Candel Therapeutics Inc (NASDAQ: CADL) set off with pace as it heaved 10.61% to $4.90, before settling in for the price of $4.43 at the close...
Quantexa News
12/06
Candel Therapeutics Inc (CADL) Volatility At 11.08%, Should You Add A Position?
Candel Therapeutics Inc (NASDAQ: CADL) is 233.33% higher on its value in year-to-date trading and has touched a low of $0.77 and a high of $14.30 in the current 52-week trading range. The question bec...
Quantexa News
12/11
MetLife Investment Management LLC Buys Shares of 12,558 Candel Therapeutics, Inc. (NASDAQ:CADL)
MetLife Investment Management LLC bought a new stake in Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and...
Quantexa News
12/11
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
December 11, 2024 at 07:00 AM EST NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical-stage biopharmaceutical company focus...
Quantexa News
12/11
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer,...
Quantexa News
12/11
Candel Therapeutics Reports Promising Phase 3 Results for CAN-2409
Author Logan Wright Updated : 12-11-2024 07:20 AM Exciting Developments from Candel Therapeutics Candel Therapeutics, Inc. (NASDAQ: CADL), a pioneering clinical-stage biopharmaceutical company, has...
Quantexa News
12/11
Candel shares surge on positive prostate cancer trial
On Wednesday, Candel Therapeutics, Inc. ( NASDAQ :CADL) experienced a significant 150% increase in its stock value following the announcement of promising results from a phase 3 clinical trial. The tr...
Quantexa News
12/11
Candel Therapeutics Announces Positive Phase 3 Trial Results for CAN-2409 in Prostate Cancer
Candel Therapeutics, Inc. recently reported positive topline data from its phase 3 randomized clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients at intermedia...
Quantexa News
12/11
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial
Candel Therapeutics, Inc. recently announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients. In the US alone, over 100,...
Quantexa News
12/11
Candel Therapeutics' (CADL) Stock Rockets After Groundbreaking Cancer Trial Results
Candel Therapeutics, Inc. (Nasdaq: CADL) has caught the attention of investors this Wednesday morning with an impressive surge in its stock price, jumping or to reach at 10:14 AM EST. This massive inc...
Quantexa News
12/11
Candel Therapeutics shares surge on positive Phase 3 results for CAN-2409 in localized prostate cancer
Candel Therapeutics Inc (NASDAQ:CADL) announced that its experimental immunotherapy, CAN-2409, met its main goal in a Phase 3 trial, significantly improving disease-free survival in patients with loca...
Yahoo Finance News
12/12
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal Zacks Equity Research Thu, Dec 12, 2024, 10:31 AM 5 min read In This Article: CADL PFE Shares of Candel Therapeutics CADL surged...
Yahoo Finance Community
12/12
Comment
Even if there is an offering, the impact to potential forward valuation will be minimal as this is already after the fact of the great P3 results. Of course meeting P3 target endpoint is not a 100% guaranteed FDA approval. But valuation will exponentially increase given the much higher probability of success and expected market size....
Votes:
5
1
Yahoo Finance News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
Candel Therapeutics Announces $80 Million Proposed Public Offering Candel Therapeutics Thu, Dec 12, 2024, 3:51 PM 5 min read In This Article: CADL +26.45% Candel Therapeutics NEEDHAM, Mass., Dec. 12,...
Polygon News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
Candel Therapeutics, a clinical-stage biopharmaceutical company, announced the launch of an $80 million public offering of its common stock and pre-funded warrants. The company plans to use the procee...
Quantexa News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
Candel Therapeutics NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
Quantexa News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
December 12, 2024 at 04:52 pm EST NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developi...
Quantexa News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Yahoo Finance Community
12/12
Comment
I am not sure why there’s such a negative AH reaction to the news. They need money to continue to fund their R&D, so they can bring it to the market. What did investors expect, for them to just stop the R&D work? This is a biotech, and they need money until they have an approval.Also, I don’t think the offering was that bad. It sounds like ATM based on what the stock does in the near future. I was afraid they’ll do like $150-200M at a deeply discounted price (i.e below $4). If this is ATM, then $80M isn’t all that dilutive, and it will give them enough cash to see through FDA approval and then some. This is good news in my opinion....
Votes:
2
3
Yahoo Finance Community
12/12
Comment
I bought at $12 don’t plan on selling anything and not looking for it just to get back to $12 to break even. I will make real money on this and not going to sweat the small stuff. Did I know an offering was possible/probable if they weren’t BO soon. Duh we all knew that. GLTA and live life like your dying cause we all are....
Votes:
3
1
Quantexa News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/12
Candel Therapeutics Announces $80 Million Proposed Public Offering
News provided by Candel Therapeutics Dec 12, 2024, 4:51 PM ET NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical...
Yahoo Finance Community
12/12
Comment
This is a company that has been very careful not to dilute shareholders. They don't have an offering with every PR. They also defended the price prior to the offering rather than dumping at a low price. $80MM resolves their "going concern" issues for a good long while. I'm still very happy with my decision to invest here and will happily add more....
Votes:
6
4
Yahoo Finance Community
12/12
Comment
If this offering adds ten, heck, even twenty million shares , it still is only a 30 to 40 million shares float, still tiny by comparison. This will mean little if nothing after this gets bought out in six months. Shorts only want to scare you out of your shares. HOLD....
Votes:
10
3
Quantexa News
12/12
Candel Therapeutics Announces Pricing of Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/12
Candel Therapeutics Announces Pricing of Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/13
Candel Therapeutics Announces Pricing of Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/13
Candel Therapeutics stock drops after pricing public offering
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) saw a 30% decrease in premarket trading today following the announcement of its public offering pricing. The biopharmaceutical company, which speciali...
Quantexa News
12/13
Candel Therapeutics stock drops after pricing public offering
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) saw a 30% decrease in premarket trading today following the announcement of its public offering pricing. The biopharmaceutical company, which speciali...
Quantexa News
12/13
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday. Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) fell sharply in today's pre-market trading...
Quantexa News
12/13
The Candel Therapeutics Inc (NASDAQ: CADL) Stock Price: Is It Overvalued?
Candel Therapeutics Inc (NASDAQ:CADL) shares, rose in value on Thursday, December 12, with the stock price up by 26.45% to the previous day's close as strong demand from buyers drove the stock to $9.8...
Quantexa News
12/13
Candel Therapeutics stock drops after pricing public offering
Shares of Candel Therapeutics, Inc. ( NASDAQ :CADL) saw a 30% decrease in premarket trading today following the announcement of its public offering pricing. The biopharmaceutical company, which specia...
Yahoo Finance Community
12/13
Comment
Buying shares near offering prices when a company’s stock is depressed due to dilution can be a highly rewarding strategy if the company grows and recovers in the long term. However, it does carry risks, especially if the company struggles post-offering or if the offering is due to financial distress....
Yahoo Finance Community
12/13
Comment
It takes 10yrs to do a phase 3 trial in early stage prostate cancer with survival end point, do you think big pharma wont gobble up a company with positive phase 3 trial in this space where nothing has been approve in 20 yrs ? the pharma with prostate business will be actively looking at this opportunity. with 80$ mil in bank these guys can start manufacturing commercial product, which they need to file BLA, it will also make them more attractive to BP....
Votes:
4
0
Quantexa News
12/13
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday. Shares of Candel Therapeutics, Inc. CADL fell sharply in today's pre-market trading after the...
Yahoo Finance Community
12/13
Comment
Could you imagine if this was done at a casino, everyone is sitting at the table and then the dealer takes all money and says" we decided to give ourselves a raise and you now owe us money. These stupid public offerings need to be presented with warning of a few days...not surprise them after the markets close...criminal immoral...f these people....
Votes:
5
3
Yahoo Finance Community
12/13
Comment
accelerated FDA approval can be granted in as little as 6 months.After FDA approval, it can take about 6 to 12 months for a cancer drug to become widely available to the public, though this can vary.Please be aware that we may see a surge of positive developments over the next 12 months....
Votes:
9
1
Yahoo Finance Community
12/13
Comment
They have the great results, they have the money, this looks like the type of offering that gets bought and bid up quickly. It will not surprise me if next week this resumes the uptrend towards $15, and this offering is in the rear view mirror very quickly....
Votes:
6
0
Yahoo Finance Community
12/13
Comment
Perhaps they priced the new 10 million share offering (with warrants at $6) at $5 so the employees who were forced to sell at $4 due to options vesting tax bills can get back in at close to what they were forced to sell for. (Too bad for them the study results came in a month too late). Just a theory, of course. Also, I don’t think the $60 million would be enough for them to market the therapy on their own, but it should be enough to keep BP from trying to starve them into submitting to a cheap acquisition....
Votes:
2
1
Yahoo Finance Community
12/13
Comment
Upcoming results will propel this meaningfully higher. Prostate is tough cold tumor cancer and they passed phase 3. Bodes well for the next 2 readouts. Look at replimune using a similar approach in melanoma. Serious money to be made here with market cap less than 300 mil...
Votes:
4
0
Yahoo Finance Community
12/14
Comment
Don’t waste your time here, folks unless you’re shorting this. Buried in the PR: “Per the data readout, treatment with the candidate demonstrated numerical improvement in time to radical treatment and the percentage of patients achieving negative (prostate cancer-free) biopsies at 1-year post treatment. However, such improvements did not reach statistical significance.” So, all this hubbub to tell us that their product is not any more effective than the placebo?...
Votes:
1
7
Yahoo Finance Community
12/14
Comment
CADL now has money for BLA submission and padding to resolve any issues with FDA. With the unmet need for a prostate cancer treatment FDA will work with CADL to get this ready for Advisory committee and approval after issues are corrected.Remember; there are options for an addition 2 million shares for the next 30 days so heggies will likely push up with analysis and visibility of Phase 3 data and revenue from sales potential....
Votes:
3
0
Quantexa News
12/14
Candel Therapeutics (CADL) Enters into Underwriting Agreement for Public Offering
Candel Therapeutics, Inc. (NASDAQ: CADL) recently disclosed its latest move in a filing with the Securities and Exchange Commission (SEC). On December 12, 2024, the biopharmaceutical company entered i...
Quantexa News
12/15
Candel Therapeutics (CADL) Enters into Underwriting Agreement for Public Offering
Candel Therapeutics, Inc. (NASDAQ: CADL) recently disclosed its latest move in a filing with the Securities and Exchange Commission (SEC). On December 12, 2024, the biopharmaceutical company entered i...
Yahoo Finance Community
12/15
Comment
don't be manipulated out of your position......“Importantly, this study was conducted under a Special Protocol Assessment agreed with the FDA, on key aspects of study design, meaning that safety and efficacy data generated from the study could be sufficient for the Company to seek regulatory approval for CAN-2409 in this indication.”...
Votes:
4
0
Yahoo Finance Community
12/15
Comment
CADL appears to be sitting on great science and pipeline ' the recent readout and dilution created hope and despair but the opportunity remains intact. The SP may go down further but at the end the merit of the drug shall prevail and the risk reward ratio would get better . $10 - 15 SP is a no brainer in 2025....
Votes:
3
0
Yahoo Finance Community
12/15
Comment
CEO : "Which will probably be done in partnerships with Pharma companies.... I've been the Global Head of Development at GSK and I know that these companies are really good at at getting this to many patients and commercializing it""Manufacturing. While we continued to advance analytical development and comparability studies successfully, and locked the process, we did not want to spend tens of millions of $$ on large scale manufacturing before data read out - a concept that we call dynamic portfolio management. Some other companies fell over because of premature, big investments in CMC. Now that we have the data and secured the funding, we press the buttons for the large GMP run and put that on stability. We will accelerate where we can, as we’ve consistently done. Meanwhile, we also advance our PDAC and NSCLC programs. This may work very well from a product in pipeline and IRA …...
Votes:
9
2
Quantexa News
12/16
Understanding the Recent Fluctuations of Candel Therapeutics Inc's (CADL) Stock
The stock of Candel Therapeutics Inc (CADL) has seen a 31.32% increase in the past week, with a 57.34% gain in the past month, and a -7.28% decrease in the past quarter. The volatility ratio for the w...
Yahoo Finance Community
12/16
Comment
"Dad, I bought shares in Candel Therapeutics, but they dropped a little." Dad: "Dropped? How much?" "About 35%." Dad: "Oh no, that’s bad! So what did you do?" "I bought more." Dad: "Wait, you bought more while it was down?!" "Yep, I’m doubling down." Dad: "I’m not sure that’s how ‘buy low, sell high’ is supposed to work..." "It’s called ‘investing with faith’—just hoping they find a cure for my portfolio!"...
Votes:
2
1
Quantexa News
12/16
Candel Therapeutics Inc (CADL)'s latest performance is not what we had anticipated
On Friday, Candel Therapeutics Inc (NASDAQ: CADL) opened lower -31.12% from the last session, before settling in for the closing price of $9.80. Price fluctuations for CADL have ranged from $1.02 to $...
Quantexa News
12/16
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
December 16, 2024 at 04:01 pm EST NEEDHAM, Mass. Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developin...
Quantexa News
12/16
Candel Therapeutics Announces Closing of Public Offering and Full Exercise
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/16
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
December 16, 2024 at 04:02 pm EST NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developi...
Quantexa News
12/16
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Quantexa News
12/16
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel") CADL, a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to h...
Quantexa News
12/16
Candel Therapeutics raises $92M in public offering following prostate cancer trial success
Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of commo...
Quantexa News
12/17
Candel Therapeutics Inc call volume above normal and directionally bullish
Bullish option flow detected in Candel Therapeutics (CADL) Inc with 2,179 calls trading, 1.2x expected, and implied vol increasing almost 2 points to 150.18%. Dec-24 7 calls and Dec-24 9 calls are the...
Quantexa News
12/18
Candel Therapeutics Inc call volume above normal and directionally bullish
Bullish option flow detected in Candel Therapeutics ( CADL ) Inc with 2,179 calls trading, 1.2x expected, and implied vol increasing almost 2 points to 150.18%. Dec-24 7 calls and Dec-24 9 calls are t...
Quantexa News
12/18
Candel Therapeutics Inc. (CADL) PT Raised to $19 at H.C. Wainwright
December 18, 2024 6:41 AM EST (Updated - December 18, 2024 6:45 AM EST) H.C. Wainwright analyst Vernon Bernardino raised the price target on Candel ... This is a premium only article. To continue r...
Quantexa News
12/18
Candel Therapeutics, Inc. (NASDAQ:CADL) Director Buys $7,500,000.00 in Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) Director Paul B. Manning bought 1,250,000 shares of the stock in a transaction on Monday, December 16th. The shares were acquired at an aver...
Quantexa News
12/20
Insider Buying: Candel Therapeutics, Inc. (NASDAQ:CADL) Director Buys 1,250,000 Shares of Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) Director Paul B. Manning acquired 1,250,000 shares of the firm's stock in a transaction on Monday, December 16th. The stock was purchased at...
Quantexa News
12/20
What is HC Wainwright's Estimate for CADL FY2024 Earnings?
Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Investment analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Candel Therapeutics in a report issued on Wednesday, Dec...
Quantexa News
12/20
Candel Therapeutics Inc (CADL) EPS growth this year is -21.37%: Get Prepared for Trading Lift Off
Candel Therapeutics Inc (NASDAQ: CADL) started the day on Thursday, with a price increase of 52.53% at $9.96, before settling in for the price of $6.53 at the close. Taking a more long-term approach,...
Quantexa News
12/21
Candel Therapeutics, Inc. (NASDAQ:CADL) Director Acquires 1,250,000 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) Director Paul B. Manning acquired 1,250,000 shares of Candel Therapeutics stock in a transaction that occurred on Monday, December 16th. The s...
Yahoo Finance Community
12/23
Comment
The only thing holding this back right now and over the remaining days of 2024 is tax loss selling. That’s all, nothing more as this will begin an upward trend in the new year. No need to do anything other than hold your core position and add on the dips. This is a sure winner. I have no idea what the size of the dip may be considering light holiday weeks volume in the days to come. It may not be noticeable in the scheme of things, i doubt more than $1 at the most. Time will tell....
Votes:
1
0
Quantexa News
12/26
6,573 Shares in Candel Therapeutics, Inc. (NASDAQ:CADL) Bought by Fmr LLC
Fmr LLC acquired a new stake in Candel Therapeutics, Inc. ( NASDAQ:CADL – Free Report ) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 6,573 shares of the comp...
Yahoo Finance Community
12/26
Comment
Started a position on this 2 weeks ago. Still doing my research and I like it so far. CEO already made it clear that he wants to involve big pharma in the distribution process , smart move. So I am confident that they will apply for FDA approval. I will continue to add on dips...
Votes:
4
0
Yahoo Finance Community
12/26
Comment
I’ve made just shy of $16k trading in and out twice now. Didn’t really want to sell, had planned to hold but I am finding this one too easy to flip. I realize that i may get caught buying back higher but I’m good with that. I am not trashing this at all. I have prostate cancer, found out in April and I am holding out for their treatment if I can. Love what they are doing. I just need to add to my savings for my family, so I have begun taking gains when and where I can....
Votes:
3
1
Yahoo Finance Community
12/26
Comment
3000 Jan 12 calls have traded in last 2 sessions ....Somebody thinking major run into JP morgan ...comments - Then here comes Pancreatic in 1st qtr.I just add more and more on the down days.....until a "real" and "true" valuation comes to fruition.Solid teenager by MAR...
Votes:
3
0
Quantexa News
12/27
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Rises By 109.6%
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 4...
Quantexa News
12/27
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Increases By 109.6%
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling...
Quantexa News
12/27
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Rises By 109.6%
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,5...
Yahoo Finance Community
12/27
Comment
This is an AI response to asking how many lives would be expected to be saved in the next five years if everyone with localized prostate cancer received Candel's therapeutic instead of the current standard of care:"Let's assume there are 100,000 new cases of prostate cancer each year in the United States. Over five years, that would be 500,000 cases. With the current standard of care, the five-year survival rate for localized prostate cancer is nearly 100%.""If CAN-2409 reduces the risk of disease progression or death by 30%, we could expect 30% more patients to survive compared to the current standard of care over five years."In other words, this may be great news, but very few lives would be saved using CAN-2409 to treat localized prostate cancer instead of the standard of care over the next five years....
Yahoo Finance Community
12/27
Comment
The way I understand the data, if prostate cancers are detected BEFORE they spread beyond the prostate, the remission rate is close to 100% for five years with the current standard of care.If, however, prostate cancer is detected AFTER it has spread, remission rates drop precipitously....
Votes:
1
0
Quantexa News
12/28
MML Investors Services LLC Sells 51,063 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)
MML Investors Services LLC lessened its holdings in Candel Therapeutics, Inc. ( NASDAQ:CADL – Free Report ) by 69.6% during the third quarter, according to the company in its most recent filing with t...
Quantexa News
12/28
MML Investors Services LLC Sells 51,063 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)
MML Investors Services LLC decreased its holdings in Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) by 69.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 22,313 shares of the...
Yahoo Finance Community
12/30
Comment
Hey folks,According to a close friend of mine (38years) who is an analyst/chartist/relatively new super AI adopter, she is predicting a fairly wide swing for a number of stocks today one of which she knew I would be interested in, yes you guessed it CADL. She is getting pretty darn accurate with her "predictions" as I call them. Overnight she shared that CADL will dramatically dip to a range between 7.97 and 8.05 before a run to around 9.32. She does feel strongly that it will close positive around 9.03. Only time will tell if she is anywhere near right. Unfortunately, I won't be around to watch the action today, heading in for some surgery that will keep me away until I can view things this later this evening. Best to all of you. Don't change a thing about how you were planning to play CADL as none of this …...
Votes:
2
0
Quantexa News
12/31
22.42% volatility in Candel Therapeutics Inc (CADL) last month: This is a red flag warning
On Monday, Candel Therapeutics Inc (NASDAQ: CADL) opened lower -10.37% from the last session, before settling in for the closing price of $8.87. Price fluctuations for CADL have ranged from $1.16 to $...
Quantexa News
12/31
You Should Look At The Stock Forecast For Candel Therapeutics Inc (NASDAQ: CADL).
In the last trading session, 2.07 million shares of the Candel Therapeutics Inc (NASDAQ:CADL) were traded, and its beta was -1.10. Most recently the company's share price was $7.95, and it changed aro...
Yahoo Finance Community
01/06
Comment
Folks,Remember 30th post. I finally spoke with my friend and she owned the prediction. She admitted not taking into consideration the tax selling impact to the recovery price within the day. I chastised her for her oversight. She did remind me that she is still learning and getting better each week. I sent her a text this morning to see if she was still watching CADL for me and she replied yes. I asked her for a “prediction for the the day. She shared she sees the low btw 8.48-8.53RG30 December, 2024Hey folks,According to a close friend of mine (38years) who is an analyst/chartist/relatively new super AI adopter, she is predicting a fairly wide swing for a number of stocks today one of which she knew I would be interested in, yes you guessed it CADL. She is getting pretty darn accurate with her "predictions" as I call them. Overnight …...
Quantexa News
01/07
Geode Capital Management LLC Grows Stake in Candel Therapeutics, Inc. (NASDAQ:CADL)
Geode Capital Management LLC lifted its stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) by 12.8% in the 3rd quarter, according to the company in its most recent 13F filing wit...
Quantexa News
01/07
Geode Capital Management LLC Buys 51,111 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)
Geode Capital Management LLC increased its stake in shares of Candel Therapeutics, Inc. ( NASDAQ:CADL – Free Report ) by 12.8% during the 3rd quarter, according to the company in its most recent discl...
Quantexa News
01/07
Candel Therapeutics Inc (CADL) ticks all the boxes for top investors with its surprise performance of 96.39% last month.
On Monday, Candel Therapeutics Inc (NASDAQ: CADL) was -5.64% drop from the session before settling in for the closing price of $9.22. A 52-week range for CADL has been $1.16 – $14.60. Here's Your FRE...
Yahoo Finance Community
01/07
Comment
RG,There are many stock analysts and chart people out there. Some good and others know nothing. My question is does your friend have any proprietary tools or information that she uses? If CADL gets anywhere near $10 on Wednesday I'm sold on her. I already have a fairly large position in CADL and am reluctant add any more at this point. Very interested to see what happens with the stock price this week....
Votes:
2
0
Quantexa News
01/07
Candel Therapeutics Inc (CADL)'s Stock Price Falls Due To Weak Fundamental Momentum
Candel Therapeutics Inc (NASDAQ:CADL) has a beta value of -1.20 and has seen 1.38 million shares traded in the last trading session. The company, currently valued at $396.83M, closed the last trade at...
Yahoo Finance Community
01/07
Comment
This is about as close to a miracle that exists which promises to be life changing for cancer patients. The CADL Website shares the following:"Candel is developing viral immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor antigens and neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor through in situ vaccination, with the potential to change disease outcomes across a variety of indications. Candel’s product candidates are designed to improve survival while maintaining quality of life in patients with early- to late-stage disease"....
Votes:
3
0
Yahoo Finance Community
01/07
Comment
Hey guys just checking in. Only have a minute as I have to step in a meeting at 230pm. Not what I was expecting to see at this point. No fear or worry though as this hasn't let me down yet. I did see some upbeat discussion about cadl on a couple of other boards yesterday. I rarely see much about it. Whoever has managed to buy in today's range could be some of the most fortunate people in the market if this runs up 22%+ tomorrow. Who knows what will happen. I thought about adding more today but I have so much now that I really don't need any more to accomplish what I want....
Votes:
1
2
Yahoo Finance Community
01/07
Comment
Meeting ended in short order as one of the Primary Attorneys was called away. Blake I'm not certain if your comment is being directed towards me, I hope not. I haven't asked or encouraged anyone to buy or sell any of shares. I wouldn't do so. I have only shared a couple of "tips" that seemed to have panned out. I almost didn't share the ne about tomorrow as I find it such a stretch. People can do as they wish and should do so. Please don't let me influence any of you in any way as I would truly feel terrible if you lost money trading this. The way I see it is that the worst that could happen is that this dips instead of rising tomorrow. If it does dip, I won't be out anything as I will hold for the bountiful returns that I feel strongly will …...
Votes:
4
2
Yahoo Finance Community
01/07
Comment
Blake,Please understand that you are not the message board baby sitter. Do you honestly believe that people here are going to "take a flier" based on information that may or may not be credible. I have the same number of shares that I had last month. I will continue to read RG's comments and see what develops. If, and it's understood to be a big "if" CADL hits 10 this week what would we all be thinking?...
Votes:
1
2
Quantexa News
01/09
Candel Therapeutics' $92 Million Common Stock Offering
Goodwin Procter represented Candel Therapeutics, Inc. in the offering, and Wilmer Cutler Pickering Hale and Dorr represented the underwriters.Candel Therapeutics, Inc. (Nasdaq: CDL) announced the pric...
Quantexa News
01/10
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of Stock
NASDAQ:CADL – Get Free Report ) insider Francesca Barone sold 13,673 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.22, fo...
Quantexa News
01/10
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of Stock
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Francesca Barone sold 13,673 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an...
Quantexa News
01/11
Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $112,392.06 in Stock
NASDAQ:CADL – Get Free Report ) insider Francesca Barone sold 13,673 shares of Candel Therapeutics stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.22, fo...
Quantexa News
01/13
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $112,392.06 in Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) insider Francesca Barone sold 13,673 shares of Candel Therapeutics stock in a transaction dated Wednesday, January 8th. The shares were sold...
Yahoo Finance News
01/13
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 Candel Therapeutics Mon, Jan 13, 2025, 5:00 AM 14 min read In This Article: CADL -5...
Quantexa News
01/13
Is Candel Therapeutics Inc (NASDAQ: CADL) Stock Set To Rise More?
In the latest trading session, 0.64 million Candel Therapeutics Inc (NASDAQ:CADL) shares changed hands as the company's beta touched -1.17. With the company's most recent per share price at $8.06 chan...
Quantexa News
01/14
Now Is The Time To Build A Position In Candel Therapeutics Inc (NASDAQ:CADL)
In the last trading session, 1.77 million Candel Therapeutics Inc (NASDAQ:CADL) shares changed hands as the company's beta touched -1.17. With the company's per share price at $7.77 changed hands at -...
Yahoo Finance Community
01/15
Comment
So they issued a Sec filing today that explains the 10 million shares they created and sold for $6, as well as the warrants (3.3 million) for $5.99 each. I can only presume that dilution has caused today’s selling even though the initial news came out in December 2024....
Votes:
6
1
Quantexa News
01/15
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Decline in Short Interest
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalli...
Yahoo Finance Community
01/15
Comment
No idea when this will bottom, though on a very positive note, phase 2 data to be released 1QT this year. With pancreatic and lung hopefully contributing positively to prostate results, CAN-2409 will have proven to work against multiple cancers. This will broaden its appeal for patients and investors alike. Only a few weeks to go!...
Votes:
3
0
Yahoo Finance Community
01/15
Comment
A Google search reveals that it takes on average one year after a Phase Three completion to submit a BLA(Biologic License Application). The company stated that it would file the BLA for prostate cancer in 4th quarter 2026 along with a BLA for Pancreatic cancer during the same time frame(it may in fact be the same BLA). This can be interpreted to mean no drug approvals or revenue for about the next two years. Large pharma does not like to buy before a drug is proven in practice: but a buyer "could" come by. So we should make sure to take this into consideration while trying to decide how much CADL to hold during the next two lean $$ years.I admit that I am disappointed that the company decided against going for a more near term 2025 BLA for prostate. There must have been some interesting internal discussion on this …...
Yahoo Finance Community
01/17
Comment
Just keep in mind this is a low float stock and easily manipulated. Facts are that at 10x this is still only a $3.5 billion dollar company for this phase III groundbreaking prostate cancer treatment, as well as potential for more cancers, an amazing platform. I'm guessing MM shaking the tree to buy your shares for the inevitable BO. I bought more this morning and will continue to buy more if it goes lower. See you all at $80 BO within a year....
Votes:
5
0
Yahoo Finance Community
01/17
Comment
shorts are going to have a field day. The catalysts are pretty much over until next year when the BLA will get done late 2026. The rest of the news is ph1 and ph2 news so unless some monster partnership is announced I expect this to drift all over the place. jmo...
Yahoo Finance Community
01/17
Comment
296 mil Mc ////115mil in cash... to complete other 2 indications.p3 completed stat sig leader in the clubhouse .<<<<<... with pancreatic and lung on the way..1x sales only in prostate is ...20-25 ....Take all the 6s you wanna sell.50 and 200 slowly continue their rise <<<<<<<<<<<by summer you will see them at 10....
Votes:
3
0
Quantexa News
01/17
Francesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider Francesca Barone sold 13,534 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an...
Quantexa News
01/17
Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
NASDAQ:CADL – Get Free Report ) CTO Seshu Tyagarajan sold 14,322 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $7.2...
Quantexa News
01/18
Francesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) insider Francesca Barone sold 13,534 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an av...
Quantexa News
01/18
Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Francesca Barone Sells 13,534 Shares
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider Francesca Barone sold 13,534 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price...
Quantexa News
01/18
Francesca Barone Sells 13,534 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Francesca Barone sold 13,534 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sol...
Quantexa News
01/18
Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) CTO Seshu Tyagarajan sold 14,322 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold a...
Quantexa News
01/19
Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $97,715.48 in Stock
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) insider Francesca Barone sold 13,534 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was...
Quantexa News
01/19
Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) CTO Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock in a transaction dated Wednesday, January 15th. The shares were sold at a...
Quantexa News
01/19
Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) CTO Seshu Tyagarajan sold 14,322 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of...
Quantexa News
01/20
Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $97,715.48 in Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider Francesca Barone sold 13,534 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price...
Quantexa News
01/20
Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $97,715.48 in Stock
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider Francesca Barone sold 13,534 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an ave...
Quantexa News
01/22
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Acquired by Barclays PLC
Barclays PLC grew its position in Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) by 327.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commiss...
Quantexa News
01/29
Candel Therapeutics Inc (CADL) is gearing up for another turning point as it hit the volume of 0.74 million
Candel Therapeutics Inc (NASDAQ: CADL) on Tuesday, soared 3.40% from the previous trading day, before settling in for the closing price of $6.48. Within the past 52 weeks, CADL's price has moved betwe...
Yahoo Finance Community
02/02
Comment
BUY THE OPEN TOMORROW ....on TARIFF REACTION .......JUST LIKE LAST FRIDAY ....ends GREEN ...NO EFFECTS!!! TIME for RECKONING in the OVERBOUGHT areas ...of Tech and bitcoin....and Allocations to the EXTREMELY UNDERVALUED << 2 MAJOR catalysts ahead back to 9-12 area...
Votes:
2
0
Yahoo Finance Community
02/03
Comment
Did you notice the filing by the CEO of sale of about 29k of his direct shares at around 7.25 recently? Why would he sell even sell a single share since there is potential upside to this stock with pancreatic and small lung cancer read out in coming days/months?...
Yahoo Finance Community
02/04
Comment
Do not sell even with today’s stock price increase with very little volume which suggest to me that this is driven by short sellers (or financial institutions taking a big stake). With enormous upside potential, with readouts expected from pancreatic and lung cancer clinical study results in first quarter, it is foolish to sell prematurely....
Votes:
1
0
Yahoo Finance Community
02/04
Comment
What I don’t get is that with the phase-3 prostate cancer results, radiation as a solo treatment produced better results than CAN–2409 did as a solo treatment. However, CAN-2409 combined with radiation was superior to all other tests. This is a very strange result since radiation as a monotherapy sure doesn’t seem like it should outperform CAN-2409 as a monotherapy. It will be interesting to see how the FDA interprets these results. I am a prostate cancer sufferer so I’m really hoping the superior combination results are construed as valid by the FDA....
Votes:
3
3
Quantexa News
02/05
Now that Candel Therapeutics Inc's volume has hit 0.98 million, investors get a glimpse of its size.
On Tuesday, Candel Therapeutics Inc (NASDAQ: CADL) opened higher 9.23% from the last session, before settling in for the closing price of $7.15. Price fluctuations for CADL have ranged from $1.21 to $...
Quantexa News
02/07
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call
The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments. Shares of Can...
Quantexa News
02/10
If You Don't Bullish On Candel Therapeutics Inc (NASDAQ: CADL) Now, You'll Regret Your Decision Later
The trading price of Candel Therapeutics Inc (NASDAQ:CADL) closed higher on Friday, February 07, and closing at $8.66, 11.03% higher than its previous close. Traders who pay close attention to intrad...
Quantexa News
02/13
Candel Therapeutics Inc (CADL) is 15.96% away from 50-day simple Moving Average despite all headwinds
Candel Therapeutics Inc (NASDAQ: CADL) started the day on Wednesday, with a price increase of 3.14% at $8.55, before settling in for the price of $8.29 at the close. Taking a more long-term approach,...
Quantexa News
02/17
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Down 9.6% in January
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 2,640,000 shares,...
Quantexa News
02/18
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Decreases By 9.6%
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totall...
Quantexa News
02/19
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totallin...
Quantexa News
02/19
Candel Therapeutics Inc (CADL) kicked off at the price of $9.52: Venture capitalists have an exciting new opportunity
A new trading day began on Tuesday, with Candel Therapeutics Inc (NASDAQ: CADL) stock price up 5.19% from the previous day of trading, before settling in for the closing price of $9.05. CADL's price h...
Quantexa News
02/19
Candel Therapeutics Inc (CADL) Stock: A Closer Look at the Market Potential
Company’s 36-month beta value is -1.23.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for CADL i...
Yahoo Finance News
02/20
Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target MT Newswires Thu, Feb 20, 2025, 7:38 AM...
Quantexa News
02/20
Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemi...
Yahoo Finance Community
02/20
Comment
looks like yesterday and today most of the shorts have covered. I'm not going to let that stop me from placing my next buy order at $11.01 that should be a safe level. It's not likely to retrace back down much below 10.70 and I don't want to miss buying back in....
Yahoo Finance Community
02/20
Comment
Ran out of steam, not to worry though. Lots of profit takers that don't realize what they bought. You can bet that they will do their best to take this down the day before any announcement so don't be shaken out! Use that drop to add additional shares...
Votes:
2
0
Quantexa News
02/20
Market Recap: Candel Therapeutics Inc (CADL)'s Positive Momentum, Closing at 10.47
For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth. The closing price of Candel Therapeutics Inc (N...
Yahoo Finance Community
02/21
Comment
What's the direction today folks? I want to add to my 10500 but don't want to be too early in doing so. Not seeing the interest this morning that we've had the past few days. Maybe a slight pullback and buying opportunity. I would have added more before now but the funds I needed cleared and show deposited today for trading....
Yahoo Finance Community
02/21
Comment
Folks based on the moderate amount of experience I have I begin to wonder if the new targets set by Cannaccord and others result in opportunities for them to "profit handsomely" on the shares they got for $6 or less. We won't find out until reporting takes place sometime later. I know that many of you have seen this play out before. Don't know for certain that was the case but it always makes me wonder....
Votes:
1
0
Quantexa News
02/22
Vontobel Holding Ltd. Sells 3,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)
Vontobel Holding Ltd. lessened its holdings in Candel Therapeutics, Inc. ( NASDAQ:CADL – Free Report ) by 13.6% in the fourth quarter, according to the company in its most recent Form 13F filing with...
Quantexa News
02/24
Candel Therapeutics Inc (CADL) with a beta value of -1.22 appears to be a promising investment opportunity.
A new trading day began on Friday, with Candel Therapeutics Inc (NASDAQ: CADL) stock price down -4.75% from the previous day of trading, before settling in for the closing price of $12.21. CADL's pric...
Quantexa News
02/25
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
NEEDHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic...
Quantexa News
02/25
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer,...
Quantexa News
02/25
Candel Therapeutics Achieves Breakthrough in Pancreatic Cancer Trials
Significant Advances in Pancreatic Cancer Research Candel Therapeutics, Inc. (Candel), a pioneering biopharmaceutical company focusing on innovative biological immunotherapies, has reported groundbre...
Quantexa News
02/25
Candel Therapeutics (CADL) Announces Positive Final Survival Data from Phase 2 Trial of CAN-2409
Candel Therapeutics, Inc. (Nasdaq: CADL ) today announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together...
Quantexa News
02/25
What Are The Analysts' Predictions For Candel Therapeutics Inc (NASDAQ: CADL)?
Candel Therapeutics Inc (NASDAQ:CADL) price closed lower on Monday, February 24, and dropping -5.76% below its previous close. A look at the daily price movement shows that the last close reads $11.6...
Quantexa News
02/25
Candel Therapeutics stock rises on positive trial data
Investing.com -- Shares of Candel Therapeutics , Inc. (NASDAQ: CADL ) climbed 8% following the announcement of favorable final survival data from their phase 2 trial of CAN-2409, a treatment for pancr...
Quantexa News
02/25
Candel Therapeutics stock rises on positive trial data
Investing.com -- Shares of Candel Therapeutics , Inc. (NASDAQ: CADL ) climbed 8% following the announcement of favorable final survival data from their phase 2 trial of CAN-2409, a treatment for pancr...
Quantexa News
02/27
Candel Therapeutics Inc (NASDAQ: CADL): How Can A Stock Be Down -2.48% Year To Date, But Still Loser
Candel Therapeutics Inc (NASDAQ:CADL)'s traded shares stood at 1.34 million during the last session, with the company's beta value hitting -1.26. At the close of trading, the stock's price was $8.47,...
Quantexa News
02/27
Candel Therapeutics Inc (CADL) recently have taken one step ahead with the beta value of -1.26
Candel Therapeutics Inc (NASDAQ: CADL) started the day on Wednesday, with a price increase of 0.95% at $8.47, before settling in for the price of $8.39 at the close. Taking a more long-term approach,...
Yahoo Finance News
02/28
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, alt...
Quantexa News
02/28
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.
Institutions' substantial holdings in Candel Therapeutics implies that they have significant influence over the company's share price 53% of the business is held by the top 9 shareholders To get a...
Quantexa News
02/28
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.
Key Insights Institutions' substantial holdings in Candel Therapeutics implies that they have significant influence over the company's share price 53% of the business is held by the top 9 shareholde...
Quantexa News
03/04
Let's Discuss The Candel Therapeutics Inc (NASDAQ: CADL) Stock Forecast.
In the last trading session, 1.13 million shares of the Candel Therapeutics Inc (NASDAQ:CADL) were traded, and its beta was -1.28. Most recently the company's share price was $7.91, and it changed aro...
Quantexa News
03/04
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Increase in Short Interest
Candel Therapeutics, Inc. ( NASDAQ:CADL – Get Free Report ) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 3,450,000 sh...
Quantexa News
03/05
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 30.7% in February
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling...
Quantexa News
03/11
Rhumbline Advisers Grows Stock Holdings in Candel Therapeutics, Inc. (NASDAQ:CADL)
Rhumbline Advisers boosted its position in Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) by 17.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 26,272 sh...
Quantexa News
03/12
CANDEL THERAPEUTICS, INC. Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2025.
Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2025. These Stock Options will be under lockup for 91 days starting from 12-DEC-2024 to 13-MAR-20...
Yahoo Finance News
03/13
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights Cand...
Quantexa News
03/13
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer,...
Quantexa News
03/13
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
Quantexa News
03/13
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
